Moderna: Insider Buy Signal

Mar. 06, 2025 4:11 PM ETModerna, Inc. (MRNA) StockMRNA206 Comments
(6min)

Summary

  • Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation.
  • Moderna cut revenue guidance for 2025 to $1.5 to $2.5 billion, though the biotech has a strong pipeline of 10 drugs targeting a $30 billion market.
  • Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities.
  • Moderna is a contrarian buy at $30, with insider buys indicating potential for a turnaround despite current financial pressures.
  • This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More »

Insider Trading Torn Paper Concept

IvelinRadkov

Moderna, Inc. (NASDAQ:MRNA) was a top contrarian pick for 2025, and the news of insider buys is a prime indication of a market shift. The company continues to be harmed by lower vaccine demand, especially with COVID-19 demand waning. My

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start March, consider joining Out Fox The Street

The service offers a model portfolio, daily updates, trade alerts and real-time chat. Sign up now for a risk-free 2-week trial. 

This article was written by

51.94K Followers

Stone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager.

Mark leads the investing group

Out Fox The Street

where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions.

Learn more

.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MRNA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About MRNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MRNA

Related Stocks

SymbolLast Price% Chg
MRNA
--